Emory University Invests $1.71 Million in Versartis, Inc. (VSAR) Stock
Emory University purchased a new stake in shares of Versartis, Inc. (NASDAQ:VSAR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 97,944 shares of the biopharmaceutical company’s stock, valued at approximately $1,709,000. Versartis makes up about 1.5% of Emory University’s investment portfolio, making the stock its 14th largest position. Emory University owned 0.28% of Versartis as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in VSAR. Perceptive Advisors LLC increased its holdings in Versartis by 6.1% during the 1st quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock valued at $94,096,000 after purchasing an additional 253,632 shares in the last quarter. Driehaus Capital Management LLC acquired a new stake in Versartis during the 1st quarter valued at $4,117,000. Renaissance Technologies LLC increased its holdings in Versartis by 334.6% during the 1st quarter. Renaissance Technologies LLC now owns 214,700 shares of the biopharmaceutical company’s stock valued at $4,584,000 after purchasing an additional 165,300 shares in the last quarter. ClariVest Asset Management LLC acquired a new stake in Versartis during the 1st quarter valued at $2,480,000. Finally, TIAA CREF Investment Management LLC increased its holdings in Versartis by 63.1% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 288,960 shares of the biopharmaceutical company’s stock valued at $5,042,000 after purchasing an additional 111,824 shares in the last quarter. 78.77% of the stock is owned by hedge funds and other institutional investors.
A number of research firms recently weighed in on VSAR. BidaskClub cut Versartis from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $26.00 price target on shares of Versartis in a report on Friday, September 8th. Zacks Investment Research cut Versartis from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $28.00 price target on Versartis and gave the company a “buy” rating in a report on Sunday, May 28th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $45.00 price target on shares of Versartis in a report on Wednesday, August 23rd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $27.88.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/14/emory-university-invests-1-71-million-in-versartis-inc-vsar-stock.html.
Versartis, Inc. (NASDAQ VSAR) remained flat at $18.20 during midday trading on Thursday. 114,177 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $18.38 and its 200-day moving average price is $18.47. The firm’s market capitalization is $647.52 million. Versartis, Inc. has a 52-week low of $9.05 and a 52-week high of $24.00.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.20). Analysts forecast that Versartis, Inc. will post ($3.49) earnings per share for the current fiscal year.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.